New York, NY — May 12, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced the appointment of Norman Relkin, MD, PhD to the Company’s…
New York, NY — May 8, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced the appointment of Bernd Metzner, PhD and Elliot Favus, MD…
New York, NY — April 29, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, other diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research study published in the current…
Preclinical Data Presented at 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy New York, NY — March 31, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer,…
New York, NY — March 27, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical…
International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (2014), Geneva, Switzerland A. Fisher, R. Medeiros, N. Bar-Ner, N. Natan, R. Brandeis, H. Elkon, V. Nahum, G. Grigoryan, M. Segal and F. Laferla View Poster
New York, NY — March 19, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014,…
Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer’s Disease and Advance Product Portfolio New York, NY — March 13, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types…
Company to Initiate Pre-Clinical Studies of ANAVEX 2-73 in ALS Models New York, NY — March 10, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, diseases of the central nervous system (CNS) and various types of cancer, today announced…
Findings Correlate with Positive Phase 1 Safety Data for ANAVEX 2-73 New York, NY — March 4, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals…
